Henry Schein, Inc. $HSIC Shares Purchased by Artisan Partners Limited Partnership

Artisan Partners Limited Partnership raised its position in Henry Schein, Inc. (NASDAQ:HSIC) by 5.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,833,041 shares of the company’s stock after purchasing an additional 370,837 shares during the quarter. Artisan Partners Limited Partnership owned about 5.80% of Henry Schein worth $453,509,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. CYBER HORNET ETFs LLC purchased a new position in Henry Schein in the second quarter valued at $25,000. MUFG Securities EMEA plc acquired a new stake in Henry Schein in the 2nd quarter valued at about $27,000. ANTIPODES PARTNERS Ltd purchased a new position in shares of Henry Schein in the 2nd quarter valued at about $43,000. Sentry Investment Management LLC grew its position in shares of Henry Schein by 132.1% during the third quarter. Sentry Investment Management LLC now owns 905 shares of the company’s stock worth $59,000 after buying an additional 515 shares in the last quarter. Finally, Evelyn Partners Investment Management Services Ltd purchased a new stake in shares of Henry Schein during the second quarter worth approximately $62,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Trading Down 0.5%

NASDAQ:HSIC opened at $81.47 on Friday. Henry Schein, Inc. has a 12-month low of $60.56 and a 12-month high of $89.29. The company has a current ratio of 1.38, a quick ratio of 0.79 and a debt-to-equity ratio of 0.59. The stock’s 50 day simple moving average is $77.75 and its 200-day simple moving average is $72.04. The firm has a market cap of $9.34 billion, a P/E ratio of 24.91, a PEG ratio of 2.43 and a beta of 0.88.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.30 by $0.04. The firm had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.34 billion. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. Henry Schein’s quarterly revenue was up 7.7% on a year-over-year basis. During the same period last year, the firm posted $1.19 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Equities analysts anticipate that Henry Schein, Inc. will post 4.74 EPS for the current year.

Analyst Upgrades and Downgrades

HSIC has been the subject of a number of recent research reports. Evercore lifted their price target on shares of Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 5th. Leerink Partners raised their price objective on shares of Henry Schein from $75.00 to $87.00 and gave the company a “market perform” rating in a report on Tuesday. UBS Group boosted their target price on shares of Henry Schein from $79.00 to $87.00 and gave the stock a “neutral” rating in a research note on Wednesday. Weiss Ratings reissued a “hold (c)” rating on shares of Henry Schein in a report on Monday, December 29th. Finally, JPMorgan Chase & Co. raised their price target on Henry Schein from $78.00 to $92.00 and gave the company an “overweight” rating in a research note on Wednesday. Six investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $85.58.

Henry Schein News Roundup

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Q4 beat and constructive outlook — Henry Schein beat EPS and revenue estimates, cited a stable dental market and set FY‑2026 EPS guidance (5.23–5.37), supporting the bullish narrative. Henry Schein beats quarterly profit estimates on stable dental market
• Positive Sentiment: Analyst upgrades and higher targets — Multiple firms raised price targets and ratings after results (notably JPMorgan to $92/overweight, UBS to $87, Mizuho/Wells Fargo lifts), signaling renewed conviction in growth and valuation support. These Analysts Increase Their Forecasts On Henry Schein After Upbeat Q4 Results
• Positive Sentiment: Independent upgrades/bullish research — Robert W. Baird upgraded HSIC and Leerink Partners published a forecast calling for strong price appreciation, adding to buying interest. Henry Schein (NASDAQ:HSIC) Upgraded at Robert W. Baird Leerink Partners Forecasts Strong Price Appreciation for Henry Schein (NASDAQ:HSIC) Stock
• Neutral Sentiment: Stock technical/market reaction — HSIC hit a 52‑week high on the post‑earnings rally, which can attract momentum flows but also profit‑taking. Henry Schein (NASDAQ:HSIC) Hits New 12-Month High on Earnings Beat
• Neutral Sentiment: Analysts reassessing story — Coverage notes that the company’s growth profile is changing and analysts are re-evaluating growth vs. valuation; this produces mixed revisions rather than uniform upgrades. How Henry Schein (HSIC) Story Is Shifting As Analysts Reassess Growth And Valuation
• Negative Sentiment: Sell‑side concerns remain — Morgan Stanley (and its analyst coverage reflected on TipRanks) continues to flag margin pressure and valuation as reasons for a Sell/underweight view with a low price target (~$58–$61), which limits consensus upside and can weigh on the stock. Henry Schein: Solid Growth but Margin Pressures and Valuation Drive Sell Rating
• Neutral Sentiment: Full Q4 transcript available for detail — Investors can review management commentary in the earnings transcript for guidance nuance and margin discussion. Henry Schein (HSIC) Q4 2025 Earnings Transcript

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.